Managing IP hosted the inaugural MIP Life Sciences Forum 2016 in New York on September 14.
Over the past year IP owners in the life sciences sector have been facing unique
opportunities and challenges when protecting their patents. Rapid developments in
the landscape of drug discovery, research and pending proposals for reform in
Congress means that your strategies to protect your IP may need rethinking.
As such, the Forum tracked legislative developments within the life sciences sector, examined the potential impact and forecasted one, five and 10-year horizon for changes. In addition, the Forum addressed:
- Strategies for patent drafting post-Gilead and gain in-depth knowledge of double patenting
- Patent prosecution trends and landmark cases including the Hatch-Waxman Act
- The changing patent landscape in Europe and considerations as to whether to opt-in or opt-out
- How to obtain an injunction and review the scope of liability
- The key decisions and precedents at PTAB over the past year
Senior IP and general counsel from leading pharmaceutical and life sciences organisations shared their experiences of managing IP matters and engaged in lively debate on all the pertinent topics within life sciences from varied perspectives.
"Well qualified speakers, latest perspectives, great forum in an intimate environment"
"Highly practical information, insights and analysis!
"The conference was very high quality and the speakers were very knowledgeable. I like that they pointed out practice tips and tried to predict where the law might go."
"The topics were ideal for the issues facing the protection of biotech IP"
"Thank you for the invitation to attend this. It really was a first-rate event."
Key takeaways from the event will be made available shortly and you can view photos from the event here.
To receive advance notice for the next year's event, email email@example.com